Skip to main content
In stock|Immunotherapy (Investigational Checkpoint)

Favezelimab

Oncology TypeBoth (Solid & Hematologic)
Drug Class / MechanismTIM-3 / LAG-3 / TIGIT Inhibitor
No Image
Description

Favezelimab is classified as a TIM-3 / LAG-3 / TIGIT Inhibitor, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational Checkpoint)
Oncology TypeBoth (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3